Detail akcie Puma online

Business Summary: Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of products to enhance cancer care. The Company is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The Company is focused on the global development and commercialization of alisertib. Alisertib is a selective, small-molecule inhibitor of Aurora Kinase A that is designed to disrupt mitosis, leading to apoptosis of rapidly proliferating tumor cells.
Financial Summary: BRIEF: For the six months ended 30 June 2026, Puma Biotechnology Inc revenues increased 3% to $101.3M. Net income decreased 50% to $4.4M. Revenues reflect Product Revenue, net increase of 3% to $95.5M. Net income was offset by Development and commercialization of innovative products segment income decrease of 65% to $3.8M. Basic Earnings per Share excluding Extraordinary Items decreased from $0.17777 to $0.08695.